Recro Pharma Inc (NASDAQ:REPH) has been assigned a consensus rating of “Buy” from the seven research firms that are currently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $11.38.

A number of brokerages have issued reports on REPH. Roth Capital reaffirmed a “neutral” rating and set a $7.50 target price (down previously from $15.00) on shares of Recro Pharma in a research report on Monday, March 25th. Oppenheimer reaffirmed an “outperform” rating and set a $9.00 target price (down previously from $19.00) on shares of Recro Pharma in a research report on Monday, March 25th. Zacks Investment Research raised Recro Pharma from a “hold” rating to a “buy” rating and set a $9.25 target price for the company in a research report on Wednesday, January 9th. ValuEngine cut Recro Pharma from a “buy” rating to a “hold” rating in a research report on Monday, March 25th. Finally, Janney Montgomery Scott reaffirmed a “buy” rating and set a $13.00 target price on shares of Recro Pharma in a research report on Thursday, January 31st.

Recro Pharma stock traded down $0.12 during trading hours on Monday, reaching $8.24. 189,458 shares of the company were exchanged, compared to its average volume of 385,274. The stock has a market capitalization of $181.21 million, a P/E ratio of -3.31 and a beta of -0.36. The company has a quick ratio of 2.08, a current ratio of 2.45 and a debt-to-equity ratio of 4.04. Recro Pharma has a 12 month low of $4.78 and a 12 month high of $13.05.

Recro Pharma (NASDAQ:REPH) last announced its earnings results on Tuesday, February 19th. The specialty pharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.17. The firm had revenue of $17.78 million during the quarter, compared to analysts’ expectations of $16.01 million. Recro Pharma had a negative return on equity of 472.58% and a negative net margin of 103.07%. Sell-side analysts anticipate that Recro Pharma will post -1.94 earnings per share for the current year.

A number of institutional investors have recently made changes to their positions in REPH. Panagora Asset Management Inc. lifted its holdings in shares of Recro Pharma by 1,361.1% during the third quarter. Panagora Asset Management Inc. now owns 189,128 shares of the specialty pharmaceutical company’s stock worth $1,345,000 after buying an additional 176,184 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Recro Pharma by 26.0% during the third quarter. Renaissance Technologies LLC now owns 480,500 shares of the specialty pharmaceutical company’s stock worth $3,416,000 after buying an additional 99,200 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Recro Pharma by 5.7% during the fourth quarter. BlackRock Inc. now owns 1,154,815 shares of the specialty pharmaceutical company’s stock worth $8,199,000 after buying an additional 62,787 shares during the last quarter. Squarepoint Ops LLC lifted its holdings in shares of Recro Pharma by 88.9% during the fourth quarter. Squarepoint Ops LLC now owns 81,794 shares of the specialty pharmaceutical company’s stock worth $581,000 after buying an additional 38,494 shares during the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of Recro Pharma during the third quarter worth approximately $156,000. 55.34% of the stock is owned by hedge funds and other institutional investors.

Recro Pharma Company Profile

Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

Featured Article: What is Green Investing?

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.